Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
about
Interventions for fatigue in Parkinson's diseaseDysregulation of glutathione homeostasis in neurodegenerative diseasesN-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line DataMechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease.Phase IIb Study of Intranasal Glutathione in Parkinson's DiseaseCentral nervous system uptake of intranasal glutathione in Parkinson's disease.NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's diseaseAstrocytes and therapeutics for Parkinson's disease.Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers.Multi-edge gene set networks reveal novel insights into global relationships between biological themes.Placebo effect of medication cost in Parkinson disease: a randomized double-blind studyA randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.Thiol-redox signaling, dopaminergic cell death, and Parkinson's diseaseGlutathione!Safety survey of intranasal glutathione.Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.Glutathione metabolism and Parkinson's disease.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.Intermittent claudication: new targets for drug development.The ongoing pursuit of neuroprotective therapies in Parkinson disease.Reduced glutathione and Parkinson's disease.DJ-1 as a Biomarker of Parkinson's Disease.Reduced Glutathione for Prevention of Renal Outcomes in Patients Undergoing Selective Coronary Angiography or Intervention.Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice.
P2860
Q24186581-D16DE76E-7FBD-4657-8BEB-F46B6951C5AEQ26822726-6CC5AED4-BEA9-4A3D-9CC2-AD6A149621C5Q30000089-FA7F62CF-A25C-4AE4-97CA-9DF2D65F1529Q30361677-C2864CA7-F0B0-48C7-AFE0-A21A63B80E46Q30365907-0EB7DD32-F857-412A-9005-9D0FC9B4206AQ33708918-D8368A70-2554-4653-B207-6E0800226EC0Q33917288-10C5DF55-193B-49E5-99C5-38E4968494C1Q33958143-F3EA8672-07E0-4C99-BC02-347F81FB5861Q34168266-F34FEAFF-4E02-440E-B482-DCA8D25CCBFBQ34211581-4AAC2A7D-5620-48A2-9260-B54EEE1AC051Q34428358-106EB1B1-02A7-4760-A65A-57FDB5B0F54DQ35134917-EEDC4B8F-B627-46BA-B118-C24425650B85Q36172557-427D7C92-4DC2-4D58-A8E0-AF995129A9BCQ36326535-738CB22E-EC5F-45BB-95C6-425DC5E51694Q36384398-3EC11409-23C8-44D0-AA87-56897648D170Q36836501-62614501-93C4-41FB-AD0A-5F335F655523Q36925905-BBE184BE-CC85-4664-976B-90206AFE7AAAQ36968109-7ED4421A-3521-4937-A28F-02A7A45C79CDQ37078480-44BE02EA-84D7-4A26-9CE3-CB9E846FFB9EQ37506492-6945F77E-AEF5-4209-87C0-1A77F8F3F683Q37603362-CA332294-D887-4BF7-A3E2-7A0A34B7068DQ38086474-73A40787-195C-4583-B712-DE088843F4EAQ38115205-677ECE48-3379-4449-BC87-08F662EE4315Q38275171-CDC5E797-746A-4F62-BC62-6E78A76B61CCQ42873902-51F04D69-6F26-4963-A423-360B1B4AEEF5Q46259808-3B0AA2F3-35E2-4B97-AF98-C853D2D57F2FQ46726762-15F23C9D-A31E-4F76-B90D-E1028B26A108Q52147727-BAA4C34B-3DDE-461F-96A6-2FD5E5C45F00
P2860
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@en
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@nl
type
label
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@en
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@nl
prefLabel
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@en
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@nl
P2093
P2860
P356
P1433
P1476
Randomized, double-blind, pilo ...... thione in Parkinson's disease.
@en
P2093
Kelly E Lyons
Summer Carter
Terry McClain
P2860
P304
P356
10.1002/MDS.22401
P407
P577
2009-05-01T00:00:00Z